DEFENSIN THERAPEUTICS ApS: Financial statements 2016
CVR: 35513280
Source: annual report 2016, Danish Business Authority
01/01/2016 – 31/12/2016
DEFENSIN THERAPEUTICS ApS (CVR 35513280) has filed annual accounts for 2016. In 2016, the company reported revenue of DKK 11,142,900 and a net result of DKK 6,028,313 compared with DKK -811,429 the year before. The profit margin was 54.1%. Equity in the 2016 report amounted to DKK 5,974,979. The solvency ratio was 77.2%. The company had 1 employee in the financial year.
- Revenue
- DKK 11,142,900
- Gross Profit
- DKK 11,142,900
- Profit/Loss
- DKK 6,028,313
- Equity
- DKK 5,974,979
- Total Assets
- DKK 7,743,762
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2016 | 11.1 mio. | 11.1 mio. | 6 mio. | 6 mio. | 1 |
| 2015 | - | - | -811 t. | -53 t. | - |
Official annual report
Find more companies like DEFENSIN THERAPEUTICS ApS
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorEvents in 2016
DEFENSIN THERAPEUTICS ApS has published its annual report for 2015. The net result was DKK -811,429.
About DEFENSIN THERAPEUTICS ApS
DEFENSIN THERAPEUTICS ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2013. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Peter Hviid Nordkild. The board consists of Ejner Bech Jensen (chair), Matthew Alister Cooper, Peter Hviid Nordkild and Robert Ehehalt. The company's owners include NOVOZYMES A/S, PN INVESTMENT ApS and NEVE INVEST ApS. The company has 0 employees (2018). In 2025, the company reported a gross profit of DKK -538,913 and a net result of DKK -539,063 compared with DKK -130,534 the year before. Equity in the 2025 report amounted to DKK 774,437.